{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:34:16Z","timestamp":1791560056536,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research","award":["23K07361"],"award-info":[{"award-number":["23K07361"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence for mirikizumab (MIRI) in pediatric ulcerative colitis (UC) is limited. We evaluate the real-world effectiveness, remission kinetics, and optimization strategies for MIRI in pediatric UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study included Japanese children with UC receiving intravenous MIRI (300\u2009mg at weeks 0, 4, 8), followed by subcutaneous maintenance (200\u2009mg every 4\u2009weeks). Those without clinical remission (CR; Pediatric Ulcerative Colitis Activity Index [PUCAI] &amp;lt; 10 plus intestinal ultrasonographic [IUS] remission) by week 12 underwent prolonged intravenous induction every 4\u2009weeks until week 24. Outcomes included CR, symptomatic remission (SR), ultrasonographic remission (UR), and endoscopic remission (ER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight children were included (median age 13\u2009years; 50% female; median PUCAI 67.5; 67.4% biologics-naive). All remission measures improved by week 12 (P\u2009&amp;lt;\u20090.001). Median time to CR was 10 (interquartile range 4-16) weeks; durable CR occurred in 27\/28 (96.4%). From weeks 12 to 52, CR, UR, and ER continued increasing, whereas SR plateaued. Prolonged induction delayed median CR (16 vs 8\u2009weeks) but most patients achieved remission by week 52. On multivariate analysis, prolonged induction was the sole independent predictor of delayed CR, whereas prior biologic exposure was not. Early IUS findings differentiated patients requiring prolonged induction or with prior biologic exposure. No serious adverse events occurred, and MIRI was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MIRI can induce and sustain CR in pediatric UC, particularly when early optimization strategies are applied. These findings highlight IUS as a useful surrogate for mucosal healing and support MIRI as a promising, adaptable, and safe therapeutic option in pediatric UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf291","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:32:53Z","timestamp":1763483573000},"page":"711-720","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Effectiveness of and Optimization Strategies for Mirikizumab in Pediatric Ulcerative Colitis: A Prospective, Observational Study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6317-4305","authenticated-orcid":false,"given":"Keisuke","family":"Jimbo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-8201","authenticated-orcid":false,"given":"Nobuyasu","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3454","authenticated-orcid":false,"given":"Mitsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musashi","family":"Hibio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Policy Evaluation, Department of Health Policy, Research Institute, National Center for Child Health and Development , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-8049","authenticated-orcid":false,"given":"Takahiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Juntendo University Faculty of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"2026040214063400100_izaf291-B1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2026040214063400100_izaf291-B2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/ijms26010121","article-title":"Key interleukins in inflammatory bowel disease\u2014a review of recent studies","volume":"26","author":"Aebisher","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026040214063400100_izaf291-B3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ibd.21383","article-title":"Acute severe ulcerative colitis in children: a systematic review","volume":"17","author":"Turner","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063400100_izaf291-B4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MPG.0b013e3182662233","article-title":"Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines","volume":"55","author":"Turner","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063400100_izaf291-B5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/jpn3.70097","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care\u2014an updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organisation","volume":"81","author":"Wine","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063400100_izaf291-B6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/jpn3.70096","article-title":"Management of paediatric ulcerative colitis, part 2: acute severe colitis\u2014an updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organization","volume":"81","author":"Assa","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026040214063400100_izaf291-B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214063400100_izaf291-B8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/ecco-jcc\/jjae088","article-title":"Early and sustained symptom control with mirikizumab in patients with ulcerative colitis in the phase 3 LUCENT programme","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026040214063400100_izaf291-B9","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026040214063400100_izaf291-B10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/psp4.13286","article-title":"Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis","volume":"14","author":"Otani","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026040214063400100_izaf291-B11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjy107","article-title":"Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: a prospective study","volume":"12","author":"Allocca","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026040214063400100_izaf291-B12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"2026040214063400100_izaf291-B13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063400100_izaf291-B14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/ecco-jcc\/jjad035","article-title":"Accuracy of transperineal ultrasonography for assessing rectal lesions in paediatric ulcerative colitis: a prospective study","volume":"17","author":"Jimbo","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214063400100_izaf291-B15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/apt.15767","article-title":"Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis","volume":"51","author":"Sagami","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063400100_izaf291-B16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00535-018-01534-w","article-title":"Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study","volume":"54","author":"Kinoshita","year":"2019","journal-title":"J Gastroenterol"},{"key":"2026040214063400100_izaf291-B17","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.3748\/wjg.v22.i21.5079","article-title":"Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse","volume":"22","author":"Nakarai","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2026040214063400100_izaf291-B18","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.3748\/wjg.v24.i38.4384","article-title":"Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis","volume":"24","author":"Urushikubo","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026040214063400100_izaf291-B19","doi-asserted-by":"crossref","first-page":"otac039","DOI":"10.1093\/crocol\/otac039","article-title":"Usefulness of the optimal cutoff value and delta value of leucine-rich alpha 2 glycoprotein in ulcerative colitis","volume":"4","author":"Matsumoto","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026040214063400100_izaf291-B20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ibd\/izab278","article-title":"Predictors of sustained response with tofacitinib therapy in patients with ulcerative colitis","volume":"28","author":"Sandborn","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063400100_izaf291-B21","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study","volume":"61","author":"Takagi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026040214063400100_izaf291-B22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/ibd\/izaf034","article-title":"Impact of psychosocial and neurodevelopmental disorders on pediatric ulcerative colitis: a single-center, retrospective, observational study","volume":"31","author":"Nakamura","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214063400100_izaf291-B23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5217\/ir.2023.00135","article-title":"Early change in serum leucine-rich \u03b1-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis","volume":"22","author":"Karashima","year":"2024","journal-title":"Intest Res"},{"key":"2026040214063400100_izaf291-B24","doi-asserted-by":"crossref","first-page":"e00174","DOI":"10.14309\/ctg.0000000000000174","article-title":"Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study","volume":"11","author":"Bertani","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"2026040214063400100_izaf291-B25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026040214063400100_izaf291-B26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026040214063400100_izaf291-B27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026040214063400100_izaf291-B28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026040214063400100_izaf291-B29","doi-asserted-by":"crossref","first-page":"jjaf005","DOI":"10.1093\/ecco-jcc\/jjaf005","article-title":"Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies","volume":"19","author":"Panaccione","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026040214063400100_izaf291-B30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center","volume":"70","author":"St-Pierre","year":"2025","journal-title":"Dig Dis Sci"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/711\/65371387\/izaf291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/711\/65371387\/izaf291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:43Z","timestamp":1775153203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/711\/8326660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf291","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,18]]}}}